comparemela.com

Latest Breaking News On - Society scientific sessions - Page 1 : comparemela.com

Cytokinetics Announces Positive Topline Data for Aficamten in SEQUOIA-HCM

On December 27, 2023, Cytokinetics announced positive topline results from the phase 3 SEQUOIA-HCM trial evaluating aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy

Cytokinetics, Incorporated (NASDAQ:CYTK) Q3 2023 Earnings Call Transcript

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.